Reply to: Pre-clinical data interpretation requires clinical context

1. Muirhead, R. et al. Pre-clinical data interpretation requires clinical context. Nature https://doi.org/10.1038/s41586-026-10774-3 (2026).

2. Piffkó, A. et al. Radiation-induced amphiregulin drives tumour metastasis. Nature 643, 810–819 (2025).

   Article  ADS  PubMed  PubMed Central  Google Scholar 

3. Palma, D. A. et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393, 2051–2058 (2019).

   Article  PubMed  Google Scholar 

4. Tsai, C. J. et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet 403, 171–182 (2024).

   Article  PubMed  Google Scholar 

5. Iyengar, P. et al. NRG-LU002: randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 42, 8506–8506 (2024).

   Article  Google Scholar 

6. Chmura, S. J. et al. NRG-BR002: a phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). J. Clin. Oncol. 40, 1007–1007 (2022).

   Article  Google Scholar 

7. Palma, D. A. et al. Measuring the integration of stereotactic ablative radiotherapy plus surgery for early-stage non-small cell lung cancer: a phase 2 clinical trial. JAMA Oncol. 5, 681–688 (2019).

   Article  PubMed  PubMed Central  Google Scholar 

8. Palma, D. A. et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J. Clin. Oncol. 38, 2830–2838 (2020).

   Article  PubMed  PubMed Central  Google Scholar 

9. O’Reilly, M. S., Holmgren, L., Chen, C. & Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2, 689–692 (1996).

   Article  PubMed  Google Scholar 

10. Krall, J. A. et al. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. Sci. Transl. Med. 10, eaan3464 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

11. Zhang, J. et al. Inflammation awakens dormant cancer cells by modulating the epithelial-mesenchymal phenotypic state. Proc. Natl Acad. Sci. USA 122, e2515009122 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

12. He, D. et al. Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps. Cancer Cell 43, 1622–1636.e7 (2025).

    Article  CAS  PubMed  Google Scholar 

13. Chia, S. B. et al. Respiratory viral infections awaken metastatic breast cancer cells in lungs. Nature 645, 496–506 (2025).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

14. Hellmann, S. & Weichselbaum, R. R. Oligometastases. J. Clin. Oncol. 13, 8–10 (1995).

    Article  Google Scholar 

15. Salama, J. K. et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 118, 2962–2970 (2012).

    Article  PubMed  Google Scholar 

Download references

Authors and Affiliations

1. Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL, USA

   Sean P. Pitroda & Ralph R. Weichselbaum

2. Ludwig Center for Cancer Research, The University of Chicago, Chicago, IL, USA

   Sean P. Pitroda & Ralph R. Weichselbaum

Contributions

S.P.P. and R.R.W. contributed equally to the conceptualization and writing of the initial paper draft. Both authors reviewed, revised and approved the final version of the paper. S.P.P. and R.R.W. jointly wrote and revised the Matters Arising rebuttal. Although the original paper included additional co-authors, the Matters Arising correspondence specifically concerns the broader clinical implications of our findings rather than the mechanistic aspects that occupied the contributions of the other authors. As S.P.P. and R.R.W. are best positioned to address questions pertaining to clinical translation and interpretation, the author list for this reply is necessarily reduced relative to that of the original article.

Corresponding author

Correspondence to Ralph R. Weichselbaum.

Competing interests

R.R.W. has stock and other ownership interests with Boost Therapeutics, Immvira, Reflexion Pharmaceuticals, Coordination Pharmaceuticals, Magi Therapeutics, Fuse Biotherapeutics and Oncosenescence. He has served in a consulting or advisory role for Aettis, Astrazeneca, Coordination Pharmaceuticals, Genus, Merck Serono, Nano proteagen, NKMax America and Shuttle Pharmaceuticals. He has received research grant funding from Varian and Regeneron, as well as NIH funding (R01CA262508 and U54 CA274291). He has received compensation including travel, accommodations or expense reimbursement from AstraZeneca, Boehringer Ingelhei and Merck Serono. S.P.P. has received research grant funding from the LUNGevity Foundation, Cancer Research Foundation, Falk Medical Research Trust and American Lung Association. R.R.W. and S.P.P. are co-founders of PersonaDx and have multiple patents pending. S.P.P. and R.R.W. have filed a patent on amphiregulin in the radiation response.